On Thursday, NBA legend Michael Jordan dropped his first NFT collection via the Heir platform.

The post “6 RINGS” early adopter wants 156,400% mark up on Michael Jordan NFT appeared first on CryptoSlate.

Welcome, Cryptonaut, to the world of tomorrow. The year is 2089. Wait, or is it 2090? Heck, who even remembers years anymore. It is late in the 21st century anyway. Earth is a dystopian place, and world governments and countries have collapsed. Humanity is ruled by corporations and franchises, and the planet is plunged into […]

The post Metaverse 101: A Beginners Guide to the Metaverse appeared first on Coin Bureau.

ESTNN provides you everything you need to know about the FNCS Chapter 3 Season 1 Finals. This weekend marks the…

The post Fortnite: How to Watch FNCS Chapter 3 Season 1 Finals & Earn Twitch Drops appeared first on Esports News Network | ESTNN.

Lausanne, Switzerland, and Barcelona, Spain, Mar 2, 2022 - (JCN Newswire) - Oculis S.A., (Oculis) a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations, and Accure Therapeutics, a private translational neuroscience R&D company, today announced a licensing agreement granting Oculis exclusive global rights to develop and commercialize ACT-01, a potentially disease-modifying therapy to protect and prevent damage to the optic nerve and retina.

ACT-01, which is being renamed OCS-05, is a first-in-class small molecule with neuroprotective activity that has shown positive results in animal models of neuroinflammation and neurodegeneration. Its mechanism of action is related to the activation of the trophic factor pathways such as IGF-1 and BDNF. In ophthalmology, this action can protect the nerve axons in conditions where the optic nerve is affected, such as in acute optic neuritis and glaucoma, where the OCS-05 could prevent chronic vision loss.

Based on positive preclinical data and results of a phase 1 safety and PK study in healthy volunteers, a phase 2a study was initiated (the ACUITY study).

ACUITY is a two-arm, randomized, double-blind, placebo-controlled, monocentric study to evaluate the safety and tolerability of OCS-05 compared to placebo in patients with acute optic neuritis. In addition to safety, secondary outcome measures will include optic nerve anatomical measures, as well as visual function measures. The study is ongoing at the La Pitie-Salpetriere hospital in Paris within the neurology-ophthalmology network of the Public University Hospital Group in Paris (APHP). One third of the planned sample size has been enrolled.
Oculis is currently planning the expansion of the program in ophthalmology working with the regulatory agencies in the US, EU and China amongst others.

Riad Sherif, M.D., CEO of Oculis, said: "We are excited about this agreement as it combines Oculis's ophthalmology expertise with Accure's unique neuroprotective approach to help transform the treatment of neurodegenerative diseases in ophthalmology. At Oculis, our focus is on building a highly innovative and differentiated pipeline providing life changing treatments for ocular unmet medical needs, and OCS-05 is a perfect fit for that ambition. Glaucoma is a leading global cause of irreversible blindness, and despite IOP lowering treatments, a significant proportion of patients still go blind. With OCS-05, we have the potential to bring to market the first neuroprotective for glaucoma and other optic neuropathies."

Laurent Nguyen, M.D., Co-founder and Chief Executive Officer at Accure Therapeutics, said: "Having shown promising early data and potential in a number of ocular disease indications, the timing is right for a partnership between two like-minded companies committed to patients and driven by a passion for neuroscience. By leveraging its expertise in ophthalmology, Oculis has the potential to fulfill the promise of this exciting asset in a wide range of neurodegenerative diseases."

In reference experimental animal models of acute optic neuritis (acute inflammatory demyelinating disorder of the optic nerve) and high-pressure glaucoma (high eye pressure damaging the optic nerve and leading to permanent vision loss), OCS-05 reduces damage to the optic nerve and retina. It also decreases paralysis progression in an autoimmune encephalomyelitis animal model for multiple sclerosis (inflammation caused by the body's immune system, which destroys nerve cell processes and myelin in the brain and spinal cord).

Data from a completed phase 1 study show the safety and tolerability of single and multiple doses of OCS-05 in healthy volunteers.

Under the terms of the agreement, Accure Therapeutics will receive an upfront payment, potential milestone payments upon the achievement of certain development and commercial milestones, and tiered royalties on sales.

Anthony Rosenberg, Chairman of Oculis's Board of Directors, said: "The addition of OCS-05 to Oculis's pipeline is very much in line with the Company's strategy to develop transformative therapies that address the root cause of ocular disease to improve patients' sight and quality of life. There is a clear need for first-in-class therapies that can protect and prevent damage to the optic nerve and retina. Oculis has the team and expertise to bring OCS-05 through clinical trials and ultimately to patients around the world."

Montserrat Vendrell, Chairman of Accure Therapeutics and Partner at Alta Life Sciences added: "This licensing deal with Oculis is a proof-of-concept of the value creation that Accure Therapeutics brings as a translational R&D engine, taking forward truly unique science that spun-off from the University of Barcelona. This licensing agreement will enhance Accure's capabilities to accelerate and expand value potential for the rest of its pipeline."

About Oculis
Oculis is a global biopharmaceutical company purposefully driven to save sight, improve eye care and address significant unmet medical needs with breakthrough innovations. Oculis's highly differentiated pipeline includes candidates for topical retinal treatments, topical biologics and disease modifying treatments. With a presence in key international markets, Oculis is poised to deliver life-changing treatments to patients worldwide.

Headquartered in Lausanne, Switzerland and with operations in Europe, the U.S. and China, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

About Accure Therapeutics
Accure Therapeutics is a private translational neuroscience R&D company. Based in Barcelona (Spain), it was launched in 2020 with a Series A funding led by Alta Life Sciences Spain I and supported by the Centre for Technological and Industrial Development (CDTI). This European company with an international mindset boasts a unique portfolio of three new chemical entity programs pursuing innovative targets - with potential to accommodate others. Accure aims to develop new disease modifying drugs to treat serious conditions such as optic neuritis, multiple sclerosis, Parkinson's disease and epilepsy. With an experienced business and scientific team, Accure Therapeutics is one of the few companies that operate in an agnostic fashion on initial science to deliver cutting-edge drugs in CNS.

To learn more visit https://accure.health/



Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comOculis S.A., (Oculis) a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations, and Accure Therapeutics, a private translational neuroscience R&D company

VRkanoid serves up gameplay you've seen a thousand times before.

Mecha Morphing has completed its private round of financing led by YGG SEA and IVC. More than 20 institutions including SHIMA Capital, Innovion, AC Capital, and Sfermion participated in the investment. The specific investment amount has not yet been disclosed. Mecha Morphing is a well-crafted fully decentralized high-quality ARPG game. The game is set in a future time. The style is a unique fusion of cyberpunk with mecha wasteland. Coupled with high-quality combat graphics, it will bring players a visual feast. Mecha Morphing is a game that was carefully created by a team with rich experience in their respective fields to ensure the success of the project. The team was carefully curated to meet the increasingly high-quality requirements of players for blockchain games and to solve the issues found in many blockchain games today. They put a lot of effort into making it both visually stimulating as well as enhancing the options for playability. It is a high-quality blockchain game that also allows players to earn while playing. Players in the world of Mecha Morphing earn income by participating in and contributing to the game’s ecosystem. The game currently includes PVE, PVP, mission system, achievement system, equipment casting upgrade system and other gameplay. In the future, this world will also add a novel skill-based PVP looting system and a PVP arena game system. The VR version will be introduced this summer for players that are interested in more immersive gameplay. Mecha Morphing had their first successful NFT launch on Binance NFT this week and is expected to have a couple more in the coming weeks.  Their highly anticipated IDO will be with Polkastarter on February 28, 2022. Be sure to follow the official Mecha Morphing channels for the latest information and updates. Website | Twitter | Telegram | Telegram Announcements | Discord  

The four-year-old Axie Infinity also made history when it reached $2.05 billion gross sales back in September 2021.

The post Axie Infinity Becomes First NFT Series to Exceed $4B in Sales appeared first on BitPinas.

Klarna, one of the most valuable financial technology firms, recently published its results for 2021. During the reported period, the company’s net operating income jumped by 38% to $1.

Safety is one of the most important topics of the crypto sphere, and with good reason. Even the most significant self-custody platforms, such as OpenSea, are vulnerable to malicious behavior and attacks. Read on to find out why security should be your number one priority, and learn from a recent, serious phishing attempt on OpenSea. What does self-custody mean? Essentially, self-custody in crypto refers to holders’ sole responsibility to handle and store their information data such as private keys. Consequently, a self-custody platform does not keep any kind of record of private keys, and thus delegates the task of safeguarding them to key owners. About the OpenSea phishing attack Phishing is a type of malicious activity that manipulates the victim into sharing confidential credentials or information, mostly by fake communication. Phishing is a serious threat even today, and it’s also one of the hardest attacks to discover, as it’s disguised as ordinary messaging. To demonstrate how real this issue is, here’s the recent case of OpenSea, one of the most important Non-Fungible Token (NFT) marketplaces of its time. According to official sources, the phishing attack influenced 32 platform users, who actually suffered damages to their holdings because of the event. The company’s CEO, David Finzer, highlighted that the attack is likely not directly connected to OpenSea’s platform, and users signed the malicious action elements somewhere else, which just underlines the significance of keeping your sensitive data safe when using a self-custody platform. Overall, while some rumors said that the stolen value was somewhere in the $200M range, David Finzer mentioned that the address, which they believe to be the hacker’s, has $1.7M to its name, which is still an outstandingly high figure. Why should safety be a priority? With the advancement of technology came the progress of hacks as well, and so nowadays, it’s more important than ever to take all the necessary precautions that aim to prevent such events. This is especially true when using self-custody platforms, since it’s the users’ responsibility to safeguard their private information, including their private keys. The reason why safety should come first is quite straightforward: the more one accumulates, the better the target for hackers, and if security is neglected, all those hard-earned funds can permanently disappear, faster than one would think. Implications of safety while trading Safety is also vital when it comes to trading cryptocurrencies, be it on a centralized exchange (CEX), or a decentralized exchange (DEX). Unfortunately, there are very few platforms out there that actually put sufficient emphasis on the topic. A great example of a DEX that ticks the box of high-level security is FOMODex, which is a multichain automated market maker (AMM), supporting Binance Smart Chain (BSC), Ethereum (ETH), and Polygon (MATIC). The platform recognized that without proper safety measures, everything else is basically useless, as results are only as good as their protection. Therefore, its team reportedly created FOMODex to be one of the most secure DEXs, despite its multichain environment and high volume of transactions. To further emphasize this, FOMODex launched as the first DEX that is regulated in the U.S., which means users’ protection is elevated, and grounds are provided for legal cases, should fraud occur. This is a remarkable achievement, as U.S. regulators are notoriously hard to get approval from. Final thoughts As demonstrated by both theory and real-world events, safety is truly one of the most overlooked, yet extremely vital aspects of dealing with cryptocurrencies. However, with next-generation platforms and users recognizing its importance, proper security will become the number one feature users look for when choosing where to conduct business in the near future.

Artificial intelligence (AI) has become a hot topic in the business and education world in recent years. Many educators are curious about how they can use AI in their classrooms, and rightfully so – there are many potential applications for this technology! This blog post will discuss ten different ways to use AI in your […]

The post 10 Ways to Use Artificial Intelligence In Education appeared first on AiiotTalk - Artificial Intelligence | Robotics | Technology.

After a difficult journey, the IEM Katowice title is an unbelievable achievement for FaZe. After a challenging road to the…

The post CS:GO: FaZe Clan Win IEM Katowice 2022 appeared first on Esports News Network | ESTNN.